Investors

Webcast
Geron at 30th Annual Piper Jaffray Healthcare Conference
Nov 27, 2018
Webcast Presentation

Geron at 30th Annual Piper Jaffray Healthcare Conference
Nov 27, 2018
Webcast
Geron at Stifel 2018 Healthcare Conference
Nov 14, 2018 at 2:00 PM EST
Webcast Presentation

Geron at Stifel 2018 Healthcare Conference
Nov 14, 2018 at 2:00 PM EST

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference in New
Toggle Summary Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December Conference call scheduled for 4:30 p.m. ET today MENLO PARK, Calif. , Nov.
Toggle Summary Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) --   Geron Corporation (Nasdaq: GERN) today announced that clinical data related to imetelstat, the Company’s

Corporate Presentation

Documents

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com